ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Twelve-month outcomes after open bleb revision for Preserflo
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the 12-month efficacy and safety of open bleb revision (OBR) for Preserflo PATIENTS AND
methodsAll consecutive patients who underwent PMS OBR for primary bleb failure between April 2019 and July 2024 at the Hôpital National des Quinze-Vingts (Paris, France) were retrospectively included. The primary endpoint was assessed at 6 and 12 months as surgical success, defined as an intraocular pressure (IOP) ≤ 21 mmHg with a ≥ 20% reduction in IOP using the same or fewer hypotensive treatments, with no additional glaucoma surgery, no chronic hypotony, and no loss of light perception. All complications during follow-up were analyzed.
resultsA total of 87 patients who underwent PMS OBR for primary bleb failure were evaluated. Most patients presented with severe, refractory, glaucoma, as the mean number of glaucoma surgical procedures prior to the first PMS implant was 1.9 ± 1.4. 97% of patients had previously undergone major bleb-forming glaucoma surgery. The mean preoperative IOP was 30.2 mmHg with 1.8 ± 1.5 hypotensive treatments. OBR was performed after a median interval of 157 days. Success rate was 40.7% at 6 months, and dropped to 20.9% at 12 months. The mean IOP decreased to 20.2 ± 7.6 mmHg at 12 months, representing a significant decrease of 9.8 ± 9.3 mmHg (33%), with 1.7 ± 1.5 hypotensive treatments (p = 0.82). Transient postoperative hypotony was observed in 3 patients (3.5%). No serious complications were reported during follow-up, in particular no chronic hypotony.
conclusionFollowing OBR for PMS bleb failure, approximately 40% of patients achieved surgical success at 6 months, compared with 20% at 12 months. However, a significant reduction in intraocular pressure was maintained at 12 months, without a statistically significant reduction in medication burden.
Indexed as
Identifiers
42213135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.